Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Prognostic and predictive potential of CXCL11 in endocrine resistance in breast cancer

Fabiana Napolitano, MD, University of Naples Federico II, Naples, Italy, explores the role of CXCL11 as a prognostic biomarker linked to relapse-free survival and a predictive factor for resistance to endocrine therapy in breast cancer. The use of CXCL11 to identify high-risk patients for treatment escalation is also discussed, which may also be useful in guiding personalized therapeutic approaches. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.